TLX: Strong imaging sales, new FDA approvals, and global trial progress drive growth
A vertically integrated radiopharma company reported strong imaging sales and expanded its global infrastructure. Recent FDA approval of Pixclara opens a new market in glioma imaging, while the BiPASS and ProstACT GLOBAL 2 trials advance the pipeline in prostate cancer. U.S. trial recruitment and i…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.